Aspen Pharmacare Holdings Limited · JSE:APN
Aspen Pharmacare — FY2011 Earnings Presentation
71 slides from Aspen Pharmacare's earnings presentation, Nov 19, 2011
Slide 1: Aspen Group Results 2011
Slide 2: Financial Performance Highlights
FINANCIAL PERFORMANCE HIGHLIGHTS Revenue +29% R12.4 billion from continuing operations Normalised headline earnings +29% R2.4 billion from continuing operations Normalised diluted headline earnings per share +20% 523.3 cents from continuing operations Capital distribution to shareholders +50% 105.0
Slide 3: Growth Record Since Listing
GROWTH RECORD SINCE LISTING from Continuing Operations Growth in Revenue since Listing CAGR = Revenue 48% Growth in HEPS since Listing 12,383 CAGR = HEPS 46% 544 456 Cents per Share 9,619 8,441 378 R'millions 210 226 4,682 185 4,026 138 3,449 104 2,815 63 79 1,561 1,890 2,202 17 26 47 936 1,104 4 73
Slide 4: Abridged Income Statement
ABRIDGED INCOME STATEMENT Year Ended Year Ended % Change 30 June 2011 30 June 2010 Continuing Operations R million R million Revenue 12 383 9 619 +29% Gross profit 5 614 4 476 +25% Net operating expenses (2 322) (1 851) EBITA 3 292 2 625 +25% Amortisation (143) (101) Operating profit 3 149 2 524 +25
Slide 5: Adjusted Income Statement
ADJUSTED* INCOME STATEMENT * Adjusted for headline earnings adjustments and to add back transaction and restructuring costs CONTINUING OPERATIONS Unadjusted Year Ended Year Ended % Change Year Ended 30 June 2011 30 June 2010 30 June 2011 R million R million R million Revenue 12 383 12 383 9 619 +29%
Slide 6: Benchmarking Performance Expectations
BENCHMARKING PERFORMANCE EXPECTATIONS CONTINUING DISCONTINUED TOTAL R millions R millions R millions Revenue 12 383 494 12 877 Normalised operating profit 3 268 58 3 326 Normalised headline earnings 2 357 44 2 401 Normalised headline earnings per share 544 cents 10 cents 554 cents Diluted normalised
Slide 7: Discontinued Operations by Business Segment
DISCONTINUED OPERATIONS BY BUSINESS SEGMENT SA SSA INTERNATIONAL TOTAL R millions R millions R millions R millions Discontinued revenue 67 - 427 494 Discontinued normalised operating profit 2 - 56 58 Discontinued normalised headline earnings 1 - 43 44 7
Slide 8: Revenue from Continuing Operations by Customer Geography
REVENUE FROM CONTINUING OPERATIONS According to Customer Geography 2010 2011 6000 +15% 5000 4000 +122% R millions 3000 +12% 2000 +43% +3% +19% 1000 0 SA Pharma SA Consumer Sub-Saharan Africa Asia Pacific Latin America Rest of the World 8
Slide 9: Group Operating Margin
GROUP OPERATING MARGIN Based on Gross Revenue and Adjusted Operating Profit 30% 29% 28% 27.2% 27.1% 26.9% 27% 26.4% 26% 25% 24% 23% Operating margin generally stable 22% 21% 20% 2008 2009 2010 2011 9
Slide 10: Regional Performance: South African Business
REGIONAL PERFORMANCE : SOUTH AFRICAN BUSINESS from Continuing Operations 2010 2011 2010 2011 55% 48% 60% 55% Gross Revenue Adjusted Operating Profit 6,296 1,934 5,575 1,639 R millions 1,102 R millions 4,309 +29% +13% 30.7% +49% +18% 29.4% 2009 2010 2011 25.6% 2009 2010 2011 Gross Revenue Adjusted Op
Slide 11: Regional Performance: Sub-Saharan Africa
REGIONAL PERFORMANCE : SUB-SAHARAN AFRICA 2010 2011 2010 2011 3% 10% 5% 9% Gross Revenue Adjusted Operating Profit 1,301 178 177 931 910 R millions R millions 72 -2% +43% -60% +145% 19.2% 13.6% 2009 2010 2011 2009 2010 2011 Gross Revenue 7.9% Adjusted Operating Profit 2009 2010 2011 Operating Margin
Slide 12: Regional Performance: International
REGIONAL PERFORMANCE : INTERNATIONAL 2010 2011 2010 2011 36% 42% 37% 40% Gross Revenue Adjusted Operating Profit 5,617 1,377 1,014 1,023 3,603 3,201 R millions R millions +13% +56% +1% +35% 31.7% 28.4% 2009 2010 2011 24.5% 2009 2010 2011 Gross Revenue Adjusted Operating Profit 2009 2010 2011 Operati
Slide 13: Disposals & Other Discontinued Businesses
DISPOSALS & OTHER DISCONTINUED BUSINESSES • Onco Laboratories Limited Disposed of with effect from 1 February 2011 Proceeds of R602 million Profit on disposal of R368 million • Balance of Co-pharma Limited Disposed of with effect from 1 July 2010 Proceeds of R26 million Profit on disposa
Slide 14: Operating Cash Flows
OPERATING CASH FLOWS 2011 2010 Change Rm Rm Cash operating profit 3 845 3 269 Changes in working capital (463) (344) Cash generated from operations 3 382 2 925 Net finance costs paid (401) (427) Tax paid (535) (465) Cash generated from operations 2 446 2 033 +20% Discontinued operations (44) (138) N
Slide 15: Abridged Balance Sheet
ABRIDGED BALANCE SHEET Year Ended Year Ended June 2011 June 2010 R'm R'm Assets Non-current assets 17 423 12 178 Tangible fixed assets 3 652 3 012 Goodwill 4 627 456 Intangible assets 8 917 8 610 Other non-current assets 227 100 Current assets 6 335 4 683 Cash 3 039 2 940 26 797 19 801 Equity and Li
Slide 16: Investment in Property Plant & Equipment
INVESTMENT IN PROPERTY PLANT & EQUIPMENT Depreciation Capital Expenditure 636 651 700 630 600 500 382 400 R’ million 289 300 215 200 168 119 60 75 100 0 2007 2008 2009 2010 2011 More than R2.5 billion in 5 years 16
Slide 17: Debt & Liquidity Trends
DEBT & LIQUIDITY TRENDS Net cash flow from operating activities Net debt 6,729 4,432 R'millions 3,428 2,446 2,011 2,033 1,292 977 652 709 2007 2008 2009 2010 2011 29% 40% 48% 24% 34% 52% 71% 60% 76% 66% Equity Debt 17
Slide 18: Borrowings Arrangements
BORROWINGS ARRANGEMENTS New arrangements have been agreed in principle with our funders Total R6.3 billion Agreements due to be signed by end of the month International SA / SSA R1.8 billion R3.5 billion • 3 separate “debt pools” independent of one another • Unsecured funding Asia Pacific R1.0 billi
Slide 19: Sigma Acquisition
SIGMA ACQUISITION • Completed on 31 January 2011 • Purchase consideration reduced from AUD900 million to AUD863 million (R6.1 billion) Based on value of take-on of working capital • Cash outflow reduced by further R169 million due to favourable cash flow hedge • Detailed exercise conducted to fair
Slide 20: Sigma Acquisition: We Said, We Did
SIGMA ACQUISITION WE SAID WE DID • HEPS close to neutral HEPS positive • Transaction and restructuring Transaction and restructuring costs of more than R100 cost of R136 million million likely • Net debt of approximately Net debt of R6.7 billion R7 billion • Gearing of 35% - 40% Gearing of 34
Slide 21: Distribution of Fund Managers
DISTRIBUTION OF FUND MANAGERS As at December 2010 As at June 2010 As at June 2011 Europe 23% South Europe 25% South Europe 19% South Africa 38% Africa 44% Africa 54% Asia Pacific Asia Pacific 3% Asia Pacific 3% Middle East Middle East 2% Middle East 1% 1% 0.4% North North North America America Ameri
Slide 22: Aspen: Our History So Far
ASPEN ~ OUR HISTORY SO FAR • From start up in 1996 to largest pharma company in South African market Number 1 in public and private market 1 in 4 scripts dispensed is for Aspen medicine • Largest in Sub-Saharan Africa Collaboration number 1 pharma company in Sub-Saharan Africa Number 1 gener
Slide 23: Aspen's Focus
ASPEN’S FOCUS Quality Affordable Medicine for All • Aspen legacy in South Africa stretches back to 1850 and to the original Lennon brand • Aspen’s business has evolved globally over the past decade – now the leading generic manufacturer in the southern hemisphere • To achieve our objectives for qual
Slide 24: Spending Growth Fell by $20 Billion in 2010
SPENDING GROWTH FELL BY $20 BILLION IN 2010, MOSTLY OCCURRING IN THE DEVELOPED MARKETS IMS Global Market Prognosis Global Growth : 2002 - 2010 24
Slide 25: Pharmerging Markets and Generics Are Drivers of Growth
PHARMERGING MARKETS AND GENERICS ARE THE ONLY DRIVERS OF GROWTH IMS Global Market Prognosis Components of Change in Total Spending 25
Slide 26: Accelerated Shift in Spending on Generics Expected
AN ACCELERATED SHIFT IN SPENDING ON GENERICS IS EXPECTED IMS Global Market Prognosis Spending by Segment 26
Slide 27: In Pharmerging Markets Growth Is Mostly from Generics
IN PHARMERGING MARKETS GROWTH IS MOSTLY FROM GENERIC DRUGS IMS Global Market Prognosis Pharmerging Spending and Growth * • Argentina, Venezuela, Mexico, Vietnam, Indonesia, Thailand, Pakistan, Egypt, Poland, South Africa, Romania & Turkey 27
Slide 28: Aspen in the South African Market
ASPEN IN THE SOUTH AFRICAN MARKET MAT Share Value Aspen Adcock Ingram Sanofi Pfizer Novartis Cipla Medpro AstraZeneca Merck & Co Johnson & Johnson Roche 18.0 17.1 17.1 17.1 17.1 17.1 17.0 16.8 16.9 17.0 17.0 16.8 16.8 16.6 Percentage share of the market 16.0 14.0 12.0 10.0 10.0 9.9 9.9 9.9 9.9 10.0
Slide 29: Aspen in the South African Market
ASPEN IN THE SOUTH AFRICAN MARKET The March 2011 Campbell Belman Confidence Predictor showed Aspen as the leading pharmaceutical company in South Africa 2011 2010 2009 Pharmacy 1 1 2 Managed Healthcare Providers 1 1 5 Managed Healthcare Funders 1 1 5 29
Slide 30: Aspen in the South African Market: Peer Review
30 10 20 30 40 50 60 70 80 0 Is financially Is financially sound sound &&secure secure Co. reports strong Has a reflect Co. performance cash flow Has clearly defined objective/strategy Has strong cash flow Is a well reputable, Ismanaged company honest & trustworthy Is reputable, honest and trustwort
Slide 31: Aspen in the South African Market: Peer Review continued
31 10 20 30 40 50 60 70 0 Senior management accessible Strong growth potential Has a clear edge Over its competitors Feel confident in its long term future Chief executive is a straight talker ASPEN Has a good record of labour relations Practices csr without ADCOCK detracting appeal Quality of its C
Slide 32: Reporting Back on the Challenges Raised at the Interim Results
REPORTING BACK ON THE CHALLENGES RAISED AT THE INTERIM RESULTS • Legislation Logistics fees and international benchmarking No SEP increase • Patent expiries : Seretide and Truvada • Loss of Pfizer infant milk license • ARV public sector margin and volume losses 32
Slide 33: Legislation
LEGISLATION • Impact on originator products • Comprehensive submission from PTG Focus is on access Significant industry push back • Impact still uncertain • Shared with GSK • Unlikely to be material to Aspen Extract figure 10.1 from the Government Gazette Page 60 – 17 December 2010 • Regulator h
Slide 34: Legislative Challenges
LEGISLATIVE CHALLENGES No SEP Increase – Margin Pressure for Local Producers • Currency impact • Local CPI factors • Currency risk FECs provide some relief • Volume growth to drive sales Margin percentage still effected, but absolute margin can be protected • Facility costs Increased local vol
Slide 35: Patent Expiration of Truvada / Seretide
PATENT EXPIRATION OF TRUVADA / SERETIDE 2011 Sales : R150 million 2011 Sales : R150 million 2012 Forecast sales : R50 million Stellar performance of brand defence Most sales lost to launch of Atripla Unit share of Seretide post patent and Foxair > Seretide pre patent • First once a day three in one
Slide 36: Seretide & Foxair Unit Performance
SERETIDE & FOXAIR UNIT PERFORMANCE FOXAIR SEREFLO HFA SERETIDE SERETIDE & FOXAIR SERETIDE PY AVE 60,000 50,000 40,000 30,000 20,000 10,000 0 July August September October November December January February March April May June 36
Slide 37: Seretide & Foxair Value Performance
SERETIDE & FOXAIR VALUE PERFORMANCE FOXAIR SEREFLO HFA SERETIDE SERETIDE & FOXAIR SERETIDE PY AVE 16,000,000 14,000,000 12,000,000 10,000,000 8,000,000 6,000,000 4,000,000 2,000,000 0 July August September October November December January February March April May June 37
Slide 38: Antiretrovirals (ARVs)
ANTIRETROVIRALS (ARVs) • How much do ARVs costs? Triple combinations cost R50 - R100 per person per month • The ARV cost for 1 million people on treatment therefore cost government about R1 billion Estimated lives on treatment is 1.3 million with a intention to double CD4 count now lowered
Slide 39: In Defence of Our Infant Milk Formula Business
IN DEFENCE OF OUR INFANT MILK FORMULA BUSINESS • Pfizer license lost Sales R250 million • Aspen has its own brand Infacare Infacare is larger than the Pfizer brand in South Africa Infacare Gold range launched Manufacturing / formulation expertise Making strong in-roads into premium market
Slide 40: Aspen & the South African Market
ASPEN & THE SOUTH AFRICAN MARKET Market Performance Total Private Market as at June 2011 R23.52bn (June 2010: R22.14bn) Other R0.68bn (R0.64bn) OTC R5.92bn (R5.47bn) Ethical/Branded R11.76bn (R11.46bn) Generics R5.16bn (R4.57bn) Units growth 2.44% (7.08%) – driven by generic volume growth 40
Slide 41: Aspen & the South African Market: MAT Market Growth
ASPEN & THE SOUTH AFRICAN MARKET MAT Market Growth – July 2010 – June 2011 MARKET ETHICAL GENERIC OTC 18 16 15.3 15.4 14.5 14 14.2 13.5 13.6 13.3 13.1 12.8 13.0 12.9 12 11.4 11.4 11.1 10.7 10.2 10.1 11.1 10.7 10 9.0 9.8 9.0 10.0 9.6 8.8 8.8 9.7 9.5 8.9 8.9 8.1 8.4 8.4 8.6 8 8.8 7.4 8.5 7.9 7.7 7.7 6
Slide 42: Aspen & the South African Market: Total Aspen Portfolio MAT Growth
ASPEN & THE SOUTH AFRICAN MARKET Total Aspen & Portfolio MAT Growth - July 2010 – June 2011 MARKET ETHICAL GENERIC OTC 20.0 18.6 18.8 18.2 18.3 18.1 Outpacing 17.8 17.1 the market 15.4 15.3 generically 14.3 14.3 14.6 15.0 13.6 13.6 12.9 13.0 12.7 11.6 13.0 13.2 12.9 13.1 11.7 12.2 12.3 11.0 12.3 11.
Slide 43: MAT Value Share of the Generics Market
ASPEN & THE SOUTH AFRICAN MARKET MAT Value Share of the Generics Market June 2011 : R5.16bn (June 2010 : R4.57bn) Pfizer 2% Pharmaplan 2% Mylan 2% Ranbaxy 1% Dr Reddys 1% Sanofi Aventis 3% Aspen 31% Lupin 4% Servier 4% Daiichi Sankyo 5% Novartis 9% Other 10% Cipla Medpro 16% Adcock Ingram 10% 43
Slide 44: Ethical vs Generic Split: MAT Value Share
44 Percentage 28% 72% 28% 72% 28% 72% 28% 72% 28% 72% 28% 72% 28% 72% 28% 72% 28% 72% 28% 72% 28% 72% 28% 72% GENERIC 28% 72% 29% 71% 29% 71% ETHICAL 29% 71% 29% 71% 29% 71% Ethical vs Generic Split – MAT Value Share 29% 71% 29% 71% 29% 71% ASPEN & THE SOUTH AFRICAN MARKET 30% 70% 30% 70% 30% 70% 31
Slide 45: Ethical vs Generic Split: MAT Counting Unit Share
45 Percentage 58% 42% 58% 42% 58% 42% 58% 42% 59% 41% 59% 41% 59% 41% 59% 41% 59% 41% 59% 41% 59% 41% 59% 41% GENERIC 59% 41% 59% 41% 59% 41% ETHICAL 60% 40% 60% 40% 60% 40% 60% Generics have a 61% volume share but 31% value share 40% 60% Ethical vs Generic Split – MAT Counting Unit Share 40% 60% 40
Slide 46: IMS Brand Classification Criteria
IMS ~ BRAND CLASSIFICATION CRITERIA Ethicals / Branded Products that are / were patent protected Schedule 3-7 products that were never patent protected Generics Dual / second brands also included here Schedule 0-2 products OTC Unscheduled and proprietary brands Nutritionals Infant milk formula Vacci
Slide 47: Further Factors for Consideration in South Africa
FURTHER FACTORS FOR CONSIDERATION IN SOUTH AFRICA • Patent losses aside, Aspen’s base private pharma business has grown 16% by value Organic and new product launches • Trust in the Aspen brand Aspen highly rated by Managed Healthcare Funders and Providers as well as GP’s Target market getting
Slide 48: Trust in the Aspen Brand
TRUST IN THE ASPEN BRAND Scripted products in the South African Private Sector Manufacturer Scripts % Share Aspen / GSK 31,462,970 24% Adcock 21,485,810 16% Cipla 8,794,958 7% Novartis 7,563,649 6% Ranbaxy 4,619,830 4% J&J 3,968,696 3% Sanofi 3,892,056 3% Pfizer 3,852,996 3% Bayer 3,372,742 3% Pharm
Slide 49: Preferential Procurement (PP)
PREFERENTIAL PROCUREMENT (PP) • Current PP legislation has little or no alignment to BEE or local production • This has often benefited imports over local production • Public listed companies enjoyed no procurement benefit or empowerment credentials • Regulations amended on 8 June 2011 and become ef
Slide 50: Aspen's Manufacturing Competitive Advantages
ASPEN’S MANUFACTURING COMPETITIVE ADVANTAGES Manufacturing Capacity & Capability is aligned to the Group’s Growth Strategy • Aspen’s strength lies in its ability to supply complexity and high volumes of products reliably and cost competitively • Manufacturing capabilities at the Port Elizabeth and E
Slide 51: Prospects in Solids Manufacturing
PROSPECTS IN SOLIDS MANUFACTURING Port Elizabeth • Approximately 4 billion tablets have been identified for transfer into Port Elizabeth over time • Transfer of these products to Port Elizabeth will mean Economies of scale will be further improved Savings on conversion 50% - 90% versus existing
Slide 52: Cost Competitiveness
COST COMPETITIVENESS Aspen in the South African Public Sector 2010 ARV Tender 2009 Solid Dosage Tender Specpharm 1% Sandoz 2% Dezzo 2% Aurobindo 3% Pharmachem 2% Strides 4% MSD 0% Biotech 2% Adcock 3% Adcock 4% Daiichi Sankyo 3% Cipla 5% Aspen 30% Cipla 3% Gulf Drug 4% Aspen 41% Abbott 10% Biogaran
Slide 53: New Product Launches – June 2011
NEW PRODUCT LAUNCHES – JUNE 2011 Value and Number of New Product Launches per Company Value of Products Launched 0-12 months No. of Products launched 0-12 months 17 10 7 5 4 4 4 2 2 1 53
Slide 54: Sub-Saharan Africa
SUB-SAHARAN AFRICA • Robust demand Sales for the region R1.3bn and operating income at • Rolling out more representation Support growing generic business R178m. Nearly 80% of sales Reps into Nigeria through the Collaboration • Dossier progress Dispatched 334 of 813 73 of the above for Nigeri
Slide 55: The Aspen DNA - To Rest Is to Rust
THE ASPEN DNA - TO REST IS TO RUST The Aspen DNA per our Australian Team “Every morning in Africa a gazelle wakes up. It knows it must move faster than the lion or it will not survive. Every morning a lion wakes up and it knows it must move faster than the slowest gazelle or it will starve. It does
Slide 56: Aspen in Asia Pacific
ASPEN IN ASIA PACIFIC Growth in Australian Base Business Revenue CAGR % = 84% including Sigma 3091 73% excluding Sigma Other R88m 3090 Sigma 1302 ZAR ‘million Base 1701 1278 915 709 509 396 309 235 65 109 7 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 56
Slide 57: Aspen in Asia Pacific: Highlights in Australia
ASPEN IN ASIA PACIFIC Highlights in Australia • 2001 start up • 2011 1 in 7 scripts for Aspen product Number 1 by sales volume ex-pharmacy Number 1 by prescriptions written Number 7 by sales value • Aspen field force rated most effective and highly regarded – independent survey by Cegedim •
Slide 58: Aspen in Asia Pacific (includes Sigma)
ASPEN IN ASIA PACIFIC (includes Sigma) Source IMS December 2010 Rank Manufacturer No. of scripts % Share 1 Aspen Australia 17,947,615 13.92 Aspen base business continues 2 Generic* 15,515,883 12.04 to perform. Growth in sales 3 GlaxoSmithKline 13,284,020 10.30 of 33% to R1.7 billion 4 Sanofi-Aventis
Slide 59: Integration Process
INTEGRATION PROCESS • Key work streams for integration include Operations Information Technology Sales and Administration All going according to plan Procurement Operational consolidation includes Tennyson – Brisbane – closed and sold Manufacturing Croydon Research Drive – Melbourne – to
Slide 60: Integration Process: Quality & Compliance
INTEGRATION PROCESS & Quality Compliance Quality Assurance Croydon QA Noble Park QA To be consolidated into single entity Dandenong QA Dandenong Quality Compliance Control Quality Croydon Noble Park Also to be consolidated Dandenong Other Croydon Head Office To be closed and sold 55000m2 site 60
Slide 61: Consolidation / Integration Process
CONSOLIDATION / INTEGRATION PROCESS • Leaner business Shaped for future competitiveness • Manufacture concentrated at Dandenong in Melbourne • Will meet all stringent regulatory requirements • Central to strategy for roll out of quality product into Asia Pacific Japanese requirements challenging
Slide 62: Aspen in Asia Pacific
ASPEN IN ASIA PACIFIC • Australia has outperformed the expectations guidance given at the half year results 5 months included in 2011 • Basketing strategy to drive sales growth One stop shop • Integration process addressing costs Aspen has global leverage • Aggressive reduction in COG’s Select
Slide 63: Aspen in Asia Pacific: Asian Roll Out Begins
ASPEN IN ASIA PACIFIC Asian Roll Out Begins • Australia launch pad for growth into Asia Quality well accepted • Intention is to convert third party structures into Aspen controlled and managed representation Needs critical mass • A CEO has been appointed for the Philippines Marcelina T. Itchon
Slide 64: SAD vs Sigma
SAD vs SIGMA The Parallels Comments Results “When the mouse swallows the We acquired R123 million of profit. elephant it tends to get indigestion” We doubled it the following year. There can only be one result. We had neither scale nor global “They have overpaid. There are no manufacturing skills ob
Slide 65: Latin America
LATIN AMERICA • Market size R$33 billion ($21 billion) 7 times the size of South Africa • Fragmented 60 000 pharmacies and 400 wholesalers • Market growing at 19% High priced market • Social pyramid shifting annually! 65
Slide 66: Latin America
LATIN AMERICA • Foundations finally in place on which to build an Aspen style business • Appointed highly energetic CEO for Brazil Alexandre Franca Ex-BMS Executive : Sales & Marketing Has Aspen DNA Passionate, focussed, decisive and driven • Cellofarm renamed Aspen • Business transformed
Slide 67: Latin America: Average Price Levels
LATIN AMERICA Average price level in Brazil & Mexico higher than in other Pharmerging Markets 0.66 Average Standard Unit Price – Retail (US$ / Unit) Average Price (US$) 0.42 0.40 0.34 0.33 0.32 0.30 0.28 0.23 0.23 0.18 0.08 0.06 0.04 USA Germany Italy France Spain Japan Canada UK Mexico Turkey Brazi
Slide 68: Latin America
LATIN AMERICA • Mexico market size US$ 7.7 billion Aspen ranked 50th • Venezuela market size US$ 6.2 billion Aspen ranked 78th Latam Sales R925m • Consolidated the geography under Mexico ROLA Simplified supply chain 11% Rationalise pack presentations Venezuela Assisted with MOQ 11% Brazil
Slide 69: Summary & Prospects
SUMMARY & PROSPECTS • Expect another year of solid growth for Aspen Growth drivers largely offshore Primarily the Asia Pacific region • South African business has performed and shown resilience Challenges raised at interims blunted Patented products and infant milks aggressively defended S
Slide 70: Summary & Prospects
SUMMARY & PROSPECTS • Organic pipeline to retain our leadership position and drive growth • Opportunity for additional collaborations with multinationals • Focus on maintaining the underlying pharma base growth rates at the 16% achieved last year • Growth of this region to drive Group sales numbers
Slide 71: Summary & Prospects
SUMMARY & PROSPECTS • Competitive edge that often underpins deal success • Anticipate increased economies of scale in South African facilities Drive improved COGs 5- 7 year opportunity • Organic pipeline strong in all regions • Strong cash generation • Reducing debt, scope for additional gearing
Aspen Pharmacare Holdings — FY2011 Earnings Presentation on 6ix